Hims & Hers Health stock falls over 3% as return to operating losses overshadows revenue growth

Hims & Hers Health stock falls over 3% as return to operating losses overshadows revenue growth
Hims & hers slides 3.23% today

Hims & Hers Health Inc (HIMS) fell 3.23% after third-quarter results showed accelerating revenue but a return to operating losses, with new product expansion and subscriber declines adding to cautious sentiment. The move is supported by broad downside pressure, as the stock remains below key moving averages and technically vulnerable.

HIMS price prediction
24H -0.29%
$17.41
48H -0.57%
$17.36
7D -2.23%
$17.07
1M -38.89%
$10.67
3M -54.07%
$8.02
6M -72.74%
$4.76
12M -59.68%
$7.04
Current price: $17.46 -1.1000 5.93%
Real-time Data 12:30
Daily range 17.14 Arrow from to Icon 18.70
Weekly range 18.45 Arrow from to Icon 20.87
Loading...

Highlights

  • Hims & Hers Health revenue grew 49% to $890.4 million in the third quarter, but the company posted a $66.1 million operating loss and lower gross margin at 57%.
  • Subscriber count increased 13% year-over-year to 2.8 million with a sequential decline of 100,000 due to reduced marketing and brand transition, as the company expanded its weight-loss drug offerings including Zepbound.
  • Shares of Hims & Hers Health trade below key moving averages with bearish momentum, expected to range between $16.75 and $19.16 over the next five sessions with a high probability of further downside.

Mixed subscriber trend and new drug lineup amid profit reversal

Hims & Hers Health reported third-quarter revenue growth of 49% to $890.4 million, which came in slightly below estimates. The company recorded an operating loss of $66.1 million for the quarter, reversing a profit posted a year ago, and gross margin fell to 57% from 74%. Subscriber numbers increased by 13% year-over-year to 2.8 million, while management cited a loss of 100,000 subscribers from the previous quarter due to scaled-back marketing and brand transitions. Hims & Hers Health further expanded its weight-loss drug lineup, securing access to Eli Lilly's Zepbound, and outlined plans to produce peptide ingredients pending regulatory clearance, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views the latest Hims & Hers Health numbers as concerning. He notes that despite robust revenue growth, the steep drop in gross margin and a return to operating losses raise red flags. Technicals point to broad-based weakness, with all key moving averages breached and oversold conditions reflecting persistent selling. He remains skeptical about a near-term turnaround, citing subscriber loss and ongoing price pressure. "I see structural risks outweighing short-term opportunities — caution is strongly advised until the downtrend is clearly reversed."
Viktoras Karapetjanc, expert at Traders Union, remains upbeat on the company’s fundamental direction despite recent setbacks. He highlights that revenue growth of 49% and a 13% rise in annual subscribers signal enduring demand and strong management execution. Expansion into new drug offerings and vertical integration bolster the medium-term outlook. Karapetjanc believes that, even amid short-term volatility, the bullish structure for HIMS remains intact. "This market offers multiple attractive setups for forward-looking investors as the growth story is far from over."
Parshwa Turakhiya, analyst, points out technically driven opportunities amid high volatility. He sees the oversold Stochastic RSI and CCI as a potential trigger for a short-lived rebound, though overall momentum remains negative. The analyst notes that price action within the $16.75 to $19.16 zone sets the stage for swift sentiment-driven moves. "Traders should watch for a sharp reversal or breakdown in this range, as momentum could swing rapidly either way."
Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Momentum deteriorates as oversold indicators meet ongoing pressure

HIMS is currently trading below its 20-day ($25.30), 50-day ($27.43), and 200-day ($26.63) moving averages, highlighting persistent downside momentum across all timeframes. The 50-day and 200-day moving average alignment still hints at a longer-term bullish structure, but near-term signals are negative. Immediate resistance is at $18.46, with support at $16.75. Momentum indicators reinforce the bearish tone, as MACD (-3.36) and ADX (26.25) indicate ongoing selling pressure. RSI is neutral, while both Stochastic RSI and the Commodity Channel Index (CCI) sit in the oversold zone, which suggests the recent decline may be approaching exhaustion or could see a short-term rebound. Bull/Bear Power is negative, confirming sellers are controlling momentum, and the Awesome Oscillator is negative as well. Persistent price weakness after an initial upside gap mirrors these broader negative signals, with volatility high at 3.68%.

Earlier, analysts noted that Hims & Hers Health faced ongoing downside momentum and persistent technical weakness despite growth initiatives. The latest results reinforce this bearish outlook, placing increased focus on support at $16.75 as the critical level for potential downside acceleration in the coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.